{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T04:54:20Z","timestamp":1777870460871,"version":"3.51.4"},"reference-count":13,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2025,7,5]],"date-time":"2025-07-05T00:00:00Z","timestamp":1751673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,7,5]],"date-time":"2025-07-05T00:00:00Z","timestamp":1751673600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Nephrol"],"DOI":"10.1007\/s40620-025-02358-7","type":"journal-article","created":{"date-parts":[[2025,7,5]],"date-time":"2025-07-05T08:38:01Z","timestamp":1751704681000},"page":"3013-3017","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Pulmonary-renal syndrome under Dostarlimab, a recent PD-1 inhibitor, in a patient with Endometrial Cancer"],"prefix":"10.1093","volume":"38","author":[{"given":"Decaestecker","family":"Antoine","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Balzer","family":"Geoffrey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gnemmi","family":"Viviane","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pagniez","family":"Marie-Sophie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ydee","family":"Amandine","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2025,7,5]]},"reference":[{"issue":"6","key":"2358_CR1","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1016\/j.ccell.2017.05.010","volume":"31","author":"G Abril-Rodriguez","year":"2017","unstructured":"Abril-Rodriguez G, Ribas A (2017) SnapShot: immune checkpoint inhibitors. Cancer Cell 31(6):848-848.e1","journal-title":"Cancer Cell"},{"issue":"19","key":"2358_CR2","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1056\/NEJMoa1510665","volume":"373","author":"RJ Motzer","year":"2015","unstructured":"Motzer RJ, Escudier B, McDermott DF, George S, Hammers HJ, Srinivas S et al (2015) Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med 373(19):1803\u20131813","journal-title":"N Engl J Med"},{"issue":"19","key":"2358_CR3","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1056\/NEJMoa1611299","volume":"375","author":"AMM Eggermont","year":"2016","unstructured":"Eggermont AMM, Chiarion-Sileni V, Grob JJ, Dummer R, Wolchok JD, Schmidt H et al (2016) Prolonged survival in stage III melanoma with ipilimumab adjuvant therapy. N Engl J Med 375(19):1845\u20131855","journal-title":"N Engl J Med"},{"issue":"2","key":"2358_CR4","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1001\/jamaoncol.2017.3064","volume":"4","author":"R Barroso-Sousa","year":"2018","unstructured":"Barroso-Sousa R, Barry WT, Garrido-Castro AC, Hodi FS, Min L, Krop IE et al (2018) Incidence of endocrine dysfunction following the use of different immune checkpoint inhibitor regimens: a systematic review and meta-analysis. JAMA Oncol 4(2):173","journal-title":"JAMA Oncol"},{"issue":"2","key":"2358_CR5","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1681\/ASN.2019070676","volume":"31","author":"FB Cortazar","year":"2020","unstructured":"Cortazar FB, Kibbelaar ZA, Glezerman IG, Abudayyeh A, Mamlouk O, Motwani SS et al (2020) Clinical features and outcomes of immune checkpoint inhibitor-associated AKI: a multicenter study. J Am Soc Nephrol f\u00e9vr 31(2):435\u2013446","journal-title":"J Am Soc Nephrol f\u00e9vr"},{"issue":"1","key":"2358_CR6","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.ekir.2020.10.002","volume":"6","author":"A Kitchlu","year":"2021","unstructured":"Kitchlu A, Jhaveri KD, Wadhwani S, Deshpande P, Harel Z, Kishibe T et al (2021) A systematic review of immune checkpoint inhibitor-associated glomerular disease. Kidney Int Rep 6(1):66\u201377","journal-title":"Kidney Int Rep"},{"issue":"22","key":"2358_CR7","doi-asserted-by":"publisher","first-page":"4564","DOI":"10.1158\/1078-0432.CCR-22-3915","volume":"29","author":"A Oaknin","year":"2023","unstructured":"Oaknin A, Pothuri B, Gilbert L, Sabatier R, Brown J, Ghamande S et al (2023) Safety, efficacy, and biomarker analyses of Dostarlimab in patients with endometrial cancer: interim results of the phase I GARNET study. Clin Cancer Res 29(22):4564\u20134574","journal-title":"Clin Cancer Res"},{"issue":"3","key":"2358_CR8","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1016\/j.kint.2016.04.008","volume":"90","author":"FB Cortazar","year":"2016","unstructured":"Cortazar FB, Marrone KA, Troxell ML, Ralto KM, Hoenig MP, Brahmer JR et al (2016) Clinicopathological features of acute kidney injury associated with immune checkpoint inhibitors. Kidney Int sept 90(3):638\u2013647","journal-title":"Kidney Int sept"},{"issue":"17","key":"2358_CR9","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.1200\/JCO.2017.77.6385","volume":"36","author":"JR Brahmer","year":"2018","unstructured":"Brahmer JR, Lacchetti C, Schneider BJ, Atkins MB, Brassil KJ, Caterino JM et al (2018) Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol 36(17):1714\u20131768","journal-title":"J Clin Oncol"},{"issue":"16","key":"2358_CR10","doi-asserted-by":"publisher","first-page":"4786","DOI":"10.3390\/jcm11164786","volume":"11","author":"K Palamaris","year":"2022","unstructured":"Palamaris K, Alexandris D, Stylianou K, Giatras I, Stofas A, Kaitatzoglou C et al (2022) Immune Checkpoint Inhibitors\u2019 Associated Renal Toxicity: a series of 12 cases. J Clin Med 11(16):4786","journal-title":"J Clin Med"},{"issue":"1","key":"2358_CR11","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1186\/s12882-023-03202-5","volume":"24","author":"Z Yang","year":"2023","unstructured":"Yang Z, Xu H, Gou S, Wu H, Hu Z (2023) Pembrolizumab induced-C3 glomerulonephritis and RBC cast nephropathy: a case report. BMC Nephrol 24(1):145","journal-title":"BMC Nephrol"},{"issue":"23","key":"2358_CR12","doi-asserted-by":"publisher","first-page":"2145","DOI":"10.1056\/NEJMoa2216334","volume":"388","author":"MR Mirza","year":"2023","unstructured":"Mirza MR, Chase DM, Slomovitz BM, de Pont Christensen R, Nov\u00e1k Z, Black D et al (2023) Dostarlimab for primary advanced or recurrent endometrial cancer. N Engl J Med 388(23):2145\u20132158","journal-title":"N Engl J Med"},{"issue":"1","key":"2358_CR13","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-003777","volume":"10","author":"A Oaknin","year":"2022","unstructured":"Oaknin A, Gilbert L, Tinker AV, Brown J, Mathews C, Press J et al (2022) Safety and antitumor activity of dostarlimab in patients with advanced or recurrent DNA mismatch repair deficient\/microsatellite instability-high (dMMR\/MSI-H) or proficient\/stable (MMRp\/MSS) endometrial cancer: interim results from GARNET\u2014a phase I, single-arm study. J Immunother Cancer janv 10(1):e003777","journal-title":"J Immunother Cancer janv"}],"container-title":["Journal of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40620-025-02358-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40620-025-02358-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40620-025-02358-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T15:59:51Z","timestamp":1777564791000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/joneph\/article\/38\/9\/3013\/8466198"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,5]]},"references-count":13,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2358"],"URL":"https:\/\/doi.org\/10.1007\/s40620-025-02358-7","relation":{},"ISSN":["1724-6059"],"issn-type":[{"value":"1724-6059","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,5]]},"assertion":[{"value":"9 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no conflict of interest to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This article does not contain any studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Written consent was obtained from the patient for publication of this case report and accompanying images.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}